News | December 17, 2025
Pfizer cuts 2026 revenue outlook amid COVID-19 & patent losses
The pharmaceutical giant now expects 2026 revenues to land between $59.5 billion and $62.5 billion
The pharmaceutical giant now expects 2026 revenues to land between $59.5 billion and $62.5 billion
Biocon will acquire the residual stake held by Mylan (Viatris) for a total consideration of US$ 815 million
Grant of Permission to manufacture and market FDC of Naproxen Delayed Release and Esomeprazole capsule (375mg/500mg + 20mg/20mg)
The agreement allows Biocon Biologics to commercialize both its Denosumab biosimilars (Vevzuo and Evfraxy) in Europe starting December 2, 2025
The fresh capital will propel Cordance into its first-in-human clinical trial
Clinical studies conducted in India demonstrated that this nebulized triple therapy rapidly improves lung function and offers better control of breathlessness
Under the agreement, Evonik will distribute InVitria’s blood-free rHSA portfolio to its biopharma customers
This marks Lupin’s first commercial product leveraging PrecisionSphere, a proprietary long-acting injectable (LAI) technology
Acquisition brings highly differentiated clinical-stage obesity candidates with potential to reshape the treatment landscape
The pharma giant's 11% rise in total revenue to $43.2 billion highlights consistent execution of its growth strategy
Subscribe To Our Newsletter & Stay Updated
